|
|
 |
|
Viewing report
|
|
|
|
Hepatitis C Virus And Therapeutics - A Global Update of Market Trends & Opportunities
Bizacumen Inc., Nov 2009, Pages: 333
Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in hepatitis C virus therapeutics market is on the verge of a major breakthrough. The Hepatitis C Virus (HCV) therapeutics development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages. Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.
These and other market data and trends are presented in 'Hepatitis C Virus And Therapeutics: A Global Update of Market Trends & Opportunities' by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
Customers who bought this item also bought
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?
The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape
Antivirals: Novel Targets, Technologies, and Dealmaking
Anti-Infectives - Global Strategic Business Report
Hepatitis C (HCV) – Pipeline Assessment and Market Forecasts to 2016
Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market
Antiviral Drugs: From Basic Discovery Through Clinical Trials
Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
Victrelis (boceprevir) - First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor Approved in The US and Telaprevir to Follow
Antivirals - Global Strategic Business Report
|
|
|
|
